



## Supplementary Material

**Article Title:** Effectiveness of Lurasidone in Patients With Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

**Author(s):** Joseph P. McEvoy, MD; Leslie Citrome, MD, MPH; David Hernandez, BA; Josephine Cucchiaro, PhD; Jay Hsu, PhD; Andrei Pikalov, MD, PhD; and Antony Loebel, MD

**DOI Number:** 10.4088/JCP.12m07992

### List of Supplementary Material for the article

1. [eTable 1](#) Summary of Most Common Treatment-Emergent Adverse Events ( $\geq 5\%$  among all subjects)
2. [eTable 2](#) Weight, Metabolic Variables and Prolactin: Median and Mean Change (standard deviation) From Baseline to LOCF Endpoint
3. [eTable 3](#) Metabolic Variables and Prolactin: Proportions of Subjects With At Least One Markedly Abnormal Value
4. [eTable 4](#) Simpson-Angus Scale, Barnes Akathisia Scale, and Abnormal Involuntary Movement Scale: Median and Mean Change (standard deviation) From Baseline to LOCF Endpoint
5. [eTable 5](#) Simpson-Angus Scale, Barnes Akathisia Scale, and Abnormal Involuntary Movement Scale: Status at LOCF Endpoint
6. [eTable 6](#) Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity of Illness and Calgary Depression Scale for Schizophrenia: Median and Mean Change (standard deviation) From Baseline to LOCF Endpoint, LS Mean (standard error), 95% CI of the LS Mean, Within-Group *P* Value and Effect Size
7. [eFigure 1](#) Time to Treatment Failure by Prior Antipsychotic Agent: Sedating (olanzapine or quetiapine) Versus Nonsedating (all others) (Kaplan-Meier)
8. [eFigure 2](#) Time to All-Cause Discontinuation by Prior Antipsychotic Agent: Sedating (olanzapine or quetiapine) Versus Nonsedating (all others) (Kaplan-Meier)

### Disclaimer

© Copyright 2013 Physicians Postgraduate Press, Inc.



# THE JOURNAL OF CLINICAL PSYCHIATRY

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

## Supplementary Appendix

Supplementary eTable 1. Summary of Most Common Treatment-Emergent Adverse Events ( $\geq 5\%$  among all subjects)

Adverse Event	Number of Subjects (%) <sup>a</sup>			
	Lurasidone 40/40 (N = 72)	Lurasidone 40/80 (N = 87)	Lurasidone 80/80 (N = 81)	Total (N = 240)
Nausea	10 (13.9)	8 (9.2)	15 (18.5)	33 (13.8)
Insomnia	3 (4.2)	16 (18.4)	12 (14.8)	31 (12.9)
Akathisia	6 (8.3)	13 (14.9)	11 (13.6)	30 (12.5)
Headache	7 (9.7)	10 (11.5)	6 (7.4)	23 (9.6)
Vomiting	4 (5.6)	6 (6.9)	7 (8.6)	17 (7.1)
Somnolence	7 (9.7)	7 (8.0)	2 (2.5)	16 (6.7)
Dry Mouth	3 (4.2)	9 (10.3)	2 (2.5)	14 (5.8)

<sup>a</sup> Percentages are based on the number of subjects in the Safety population.

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

**Supplementary eTable 2. Weight, metabolic variables and prolactin – Median and mean change (standard deviation) from Baseline to LOCF Endpoint**

Outcome	Lurasidone 40/40 (N = 72)	Lurasidone 40/80 (N = 87)	Lurasidone 80/80 (N = 81)	Total (N = 240)
Weight (kg)	-0.5, -0.3 (2.7)	0.1, -0.2 (3.2)	-0.2, -0.4 (2.5)	-0.2, -0.3 (2.8)
Body Mass Index (kg/m <sup>2</sup> )	-0.2, -0.1 (0.9)	0, -0.1 (1.1)	-0.1, -0.1 (0.8)	-0.1, -0.1 (0.9)
Waist circumference (cm)	0, 0 (3.7)	0, 0 (4.1)	0, 0.4 (6.1)	0, 0.2 (4.7)
Cholesterol, overall (mg/dL)	2.5, -1.0 (22.3)	-3, -4 (21.3)	0, -0.7 (23.9)	-1, -2.0 (22.4)
High-density lipoprotein, overall (mg/dL)	1, 1.5 (10.0)	-0.5, -0.3 (9.1)	1, 1.2 (8.0)	1, 0.8 (9.1)
Low-density lipoprotein, overall (mg/dL)	-4.5, -4.6 (22.8)	0, 0.8 (21.9)	3, 1.8 (23.7)	0, -0.5 (22.9)
Triglycerides, overall (mg/dL)	4.5, 10 (53.3)	-19, 23.1 (63.7)	-7, -17.5 (56.1)	-6, -11.3 (59.7)
Glucose, overall (mg/dL)	1, 3.7 (20.6)	0, -0.2 (15.0)	-4, -3.2 (13.8)	-1, 0 (16.7)
HbA1c (%)	-0.1, 0 (0.3)	0.1, 0 (0.3)	-0.1, 0 (0.3)	0, 0 (0.3)
Insulin (mU/L)	0.1, 3.7 (22.5)	0, -0.3 (10.0)	0, -3.2 (22.9)	0, -0.1 (19.2)
C-Reactive protein (mg/dL)	0, 0 (0.5)	0, 0 (0.5)	0, -0.1 (1.2)	0, 0 (0.8)
Prolactin (ng/mL), male	-0.5, -2.6 (12.3)	0.7, 1.5 (11.9)	0.1, -0.5 (14.9)	0.1, -0.5 (13.2)
Prolactin (ng/mL), female	1.7, -1.9 (21.1)	1.1, -0.2 (24.2)	-0.1, 9.6 (47.9)	0.8, 2.0 (31.8)

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

**Supplementary eTable 3. Metabolic Variables and Prolactin – Proportions of Subjects With at Least One Markedly Abnormal Value <sup>a</sup>**

Outcome	Number of Subjects (%)			
	Lurasidone 40/40 (N = 72)	Lurasidone 40/80 (N = 87)	Lurasidone 80/80 (N = 81)	Total (N = 240)
Cholesterol, total ≥ 300 mg/dL	0/57 (0.0%)	0/71 (0.0%)	0/65 (0.0%)	0/193 (0.0%)
Cholesterol, LDL ≥ 200 mg/dL	0/57 (0.0%)	0/71 (0.0%)	0/65 (0.0%)	0/193 (0.0%)
Triglycerides ≥ 300 mg/dL	3/57 (5.3%)	0/71 (0.0%)	2/65 (3.1%)	5/193 (2.6%)
Glucose > 160 mg/dL	1/57 (1.8%)	0/72 (0.0%)	0/65 (0.0%)	1/194 (0.5%)
HbA1c ≥ 7.5%	0/66 (0.0%)	1/80 (1.3%)	0/72 (0.0%)	1/218 (0.5%)
Prolactin ≥ 5x upper limit of normal	0/66 (0.0%)	0/80 (0.0%)	2/73 (2.7%)	2/219 (0.9%)

<sup>a</sup> Cholesterol, triglycerides and glucose are confirmed fasting as per protocol; number of subjects for which data was available ranged from 192 to 220.

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

**Supplementary eTable 4. Simpson-Angus Scale, Barnes Akathisia Scale and Abnormal Involuntary Movement Scale - Median and Mean Change (Standard Deviation) from Baseline to LOCF Endpoint**

<b>Rating Scale</b>	<b>Lurasidone 40/40 (N = 70)</b>	<b>Lurasidone 40/80 (N = 81)</b>	<b>Lurasidone 80/80 (N = 80)</b>	<b>Total (N = 231)</b>
Simpson-Angus Scale	0, 0 (0.2)	0, 0 (0.2)	0, 0 (0.2)	0, 0 (0.2)
Barnes Akathisia Scale	0, 0.1 (1.1)	0, -0.1 (1.0)	0, -0.2 (1.3)	0, -0.1 (1.1)
Abnormal Involuntary Movement Scale	0, -0.3 (1.1)	0, 0 (1.3)	0, 0.1 (0.9)	0, 0 (1.1)

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

**Supplementary eTable 5. Simpson-Angus Scale, Barnes Akathisia Scale and Abnormal Involuntary Movement Scale – status at LOCF endpoint**

Rating Scale	Number of Subjects (%)			
	Lurasidone 40/40 (N = 70)	Lurasidone 40/80 (N = 81)	Lurasidone 80/80 (N = 80)	Total (N = 231)
Simpson-Angus Scale				
Abnormal (mean score > 0.3)	3 (4.3)	3 (3.7)	2 (2.5)	8 (3.5)
Normal	67 (95.7)	78 (96.3)	78 (97.5)	223 (96.5)
Barnes Akathisia Scale, Global Assessment				
Worsened	5 (7.1)	6 (7.4)	5 (6.3)	16 (6.9)
Unchanged	59 (84.3)	67 (82.7)	65 (81.3)	191 (82.7)
Improved	6 (8.6)	8 (9.9)	10 (12.5)	24 (10.4)
Abnormal Involuntary Movement Scale, Global Severity				
Worsened	2 (2.9)	2 (2.5)	6 (7.5)	10 (4.3)
Unchanged	61 (87.1)	76 (93.8)	70 (87.5)	207 (89.6)
Improved	7 (10.0)	3 (3.7)	4 (5.0)	14 (6.1)

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

**Supplementary eTable 6. Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity and Calgary Depression Scale for Schizophrenia - Median and Mean Change (Standard Deviation) from Baseline to LOCF Endpoint, LS Mean (Standard Error), 95% CI of the LS Mean, Within-Group p-Value and Effect size <sup>a</sup>**

Rating Scale	Lurasidone 40/40 (N = 69)	Lurasidone 40/80 (N = 85)	Lurasidone 80/80 (N = 81)	Total (N = 235)
Positive and Negative Syndrome Scale				
Median change	-7	-5	-7	-7
Mean change (Standard Deviation)	-5.3 (11.9)	-5.1 (9.5)	-6.8 (10.2)	-5.8 (10.5)
LS Mean (Standard Error)	-5.2 (1.2)	-5.0 (1.1)	-5.7 (1.1)	-5.3 (0.7)
95% CI for LS Mean	-7.5, -2.8	-7.1, -2.8	-7.9, -3.5	-6.6, -3.9
Within-group p-value	<0.0001	<0.0001	<0.0001	<0.0001
Effect size, Cohen's <i>d</i>	0.4	0.5	0.7	0.5
Clinical Global Impressions-Severity				
Median change	0	0	0	0
Mean change (Standard Deviation)	-0.2 (0.8)	-0.3 (0.7)	-0.3 (0.6)	-0.3 (0.7)
LS Mean (Standard Error)	-0.2 (0.1)	-0.3 (0.1)	-0.2 (0.1)	-0.2 (0.0)
95% CI for LS Mean	-0.4, -0.1	-0.4, -0.1	-0.4, -0.1	-0.3, -0.2
Within-group p-value	0.0014	<0.0001	0.0004	<0.0001
Effect size, Cohen's <i>d</i>	0.3	0.5	0.5	0.4
Calgary Depression Scale for Schizophrenia				
Median change	0	-1	-1	-1
Mean change (Standard Deviation)	-0.9 (4.0)	-1.3 (4.0)	-1.6 (2.9)	-1.3 (3.7)
LS Mean (Standard Error)	-0.7 (0.4)	-1.1 (0.3)	-1.3 (0.3)	-1.0 (0.2)
95% CI for LS Mean	-1.4, -0.0	-1.7, -0.4	-2.0, -0.7	-1.5, -0.6
Within-group p-value	0.0612	0.0011	<0.0001	<0.0001
Effect size, Cohen's <i>d</i>	0.2	0.3	0.6	0.4

<sup>a</sup> Intent-To-Treat population

40/40 – lurasidone 40 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks


40/80 – lurasidone 40 mg/d for 7 days, then 80 mg/d for 7 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

80/80 – lurasidone 80 mg/d for 14 days, followed by flexible dosing between 40 and 120 mg/d for 4 weeks

McEvoy JP, Citrome L, Hernandez D, Cucchiari J, Hsu J, Pikalov A, Loebel A. Effectiveness of Lurasidone in Schizophrenia or Schizoaffective Disorder Patients Switched from Other Antipsychotics: A Randomized, Six-Week, Open-Label, Study. *Journal of Clinical Psychiatry*, 2013. doi:10.4088/JCP.12m07992




**Supplementary eFigure 1. Time to treatment failure by prior antipsychotic agent: sedating (olanzapine or quetiapine) versus non-sedating (all others) (Kaplan-Meier)**



Log rank p-value = 0.1008

McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A. Effectiveness of Lurasidone in Schizophrenia or Schizoaffective Disorder Patients Switched from Other Antipsychotics: A Randomized, Six-Week, Open-Label, Study. *Journal of Clinical Psychiatry*, 2013. doi:10.4088/JCP.12m07992

**Supplementary eFigure 2. Time to all-cause discontinuation by prior antipsychotic agent: sedating (olanzapine or quetiapine) versus non-sedating (all others) (Kaplan-Meier)**



Log rank p-value = 0.0368

McEvoy JP, Citrome L, Hernandez D, Cucchiari J, Hsu J, Pikalov A, Loebel A. Effectiveness of Lurasidone in Schizophrenia or Schizoaffective Disorder Patients Switched from Other Antipsychotics: A Randomized, Six-Week, Open-Label, Study. *Journal of Clinical Psychiatry*, 2013. doi:10.4088/JCP.12m07992